AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The primary goal of AMAG and its maternal health division, Lumara Health, is to bring to market therapies that provide clear benefits and improve patients' lives. In addition to continuing to pursue opportunities to make new advancements in patients' health and to enhance treatment accessibility, AMAG intends to continue to expand and diversify its portfolio through the in-license or purchase of additional pharmaceutical products or companies.
Waltham, US
Size (employees)
545 (est)-1%
AMAG Pharmaceuticals was founded in 1981 and is headquartered in Waltham, US

AMAG Pharmaceuticals Office Locations

AMAG Pharmaceuticals has an office in Waltham
Waltham, US (HQ)
1100 Winter St

AMAG Pharmaceuticals Data and Metrics

AMAG Pharmaceuticals Financial Metrics

AMAG Pharmaceuticals's revenue was reported to be $532.1 m in FY, 2016 which is a 27% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

532.1 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

511.5 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(2.5 m)

EBIT (FY, 2016)

78.9 m

Market capitalization (26-May-2017)

658.9 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

274.3 m
AMAG Pharmaceuticals's current market capitalization is $658.9 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


80.9 m124.4 m418.3 m532.1 m

Revenue growth, %


Cost of goods sold

12 m20.3 m10 m20.6 m

Gross profit

68.9 m104.1 m408.3 m511.5 m

Gross profit Margin, %


Operating expense total

80.5 m107.9 m297.1 m453.2 m


(7.6 m)(3.8 m)111.2 m78.9 m

EBIT margin, %


Interest expense

(14.7 m)(53.3 m)(73.2 m)

Interest income

3.1 m

Pre tax profit

(9.6 m)9.1 m

Income tax expense

153.2 m7.1 m11.5 m

Net Income

(9.6 m)135.8 m32.8 m(2.5 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


27 m119.3 m228.7 m274.3 m

Accounts Receivable

6.8 m38.2 m85.7 m92.4 m


17.2 m40.6 m40.6 m37.3 m

Current Assets

244.4 m274 m606.7 m718.6 m


1.8 m1.5 m28.7 m24.5 m


205.8 m639.2 m639.5 m

Total Assets

265.5 m1.4 b2.5 b2.5 b

Accounts Payable

2.6 m7.3 m4.9 m3.7 m

Current Liabilities

33.1 m166.5 m245.9 m312.9 m

Additional Paid-in Capital

641.9 m793.8 m1.2 b1.2 b

Retained Earnings

(466.3 m)(330.4 m)(297.7 m)(300.1 m)

Total Equity

172.4 m460 m932.3 m934.4 m

Financial Leverage

1.5 x3 x2.7 x2.7 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(9.6 m)135.8 m32.8 m(2.5 m)

Depreciation and Amortization

3.1 m7 m69.1 m99.9 m

Accounts Receivable

(432 k)3.6 m(37 m)(9.9 m)


(1 m)(1.4 m)(5.2 m)(2.4 m)

Accounts Payable

(5.7 m)10.7 m7.9 m49 m

Cash From Operating Activities

(6.8 m)11.4 m96 m246.2 m

Capital Expenditures

(1.6 m)(147 k)(5.5 m)

Cash From Investing Activities

(13.9 m)(432.9 m)(899 m)(72.7 m)

Cash From Financing Activities

1.4 m513.8 m912.5 m(127.9 m)

Interest Paid

28 m62.4 m

Income Taxes Paid

2.4 m5.3 m

Free Cash Flow

(5.1 m)11.6 m251.7 m
Y, 2016

Financial Leverage

2.7 x

AMAG Pharmaceuticals Market Value History

AMAG Pharmaceuticals Company Life and Culture

You may also be interested in